Related Experiment Video
Updated: Dec 9, 2025
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Inhibition of Glycogen Synthase Kinase 3β Alleviates Chronic Renal Allograft Dysfunction in Rats
Jin Deng1, Xin Wang2, Qin Zhou2
1Department of Nephrology, The First Affiliated Hospital of University of South China, Hengyang, China.
Background:
Chronic renal allograft dysfunction (CRAD) is a major condition that impedes the long-term survival of renal allografts. However, the mechanism of CRAD is obscure, and the effective strategies for controlling the progression of CRAD are lacking. The present study used a CRAD rat model to assess the effect of glycogen synthase kinase 3β (GSK-3β) inhibition on the development of CRAD.
Methods:
A classical F334-to-LEW orthotopic renal transplantation was performed on the CRAD group. The treatment group was treated with the GSK-3β inhibitor 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione for 12 consecutive weeks following renal transplantation. The study included uninephrectomized F344 and Lewis rats as control subjects. Twelve weeks post surgery, the rats were retrieved for analysis of renal function, urine protein levels, histological, immunohistochemical, and molecular biological parameters.
Results:
Administration of 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione inactivated GSK-3β and thereby improved renal function, attenuated proteinuria, and reduced renal tissue damage in CRAD rats. Besides, inactivation of GSK-3β inhibited nuclear factor-κB activation, macrophage infiltration, and expression of multiple proinflammatory cytokines/chemokines. Inhibition of GSK-3β also decreased the levels of malondialdehyde, increased superoxide dismutase levels, upregulated the expression of heme oxygenase-1 and NAD(P)H quinone oxidoreductase-1, and enhanced nuclear translocation of nuclear factor erythroid 2-related factor 2 in the kidneys of CRAD rats.
Conclusions:
Inhibition of GSK-3β attenuates the development of CRAD by inhibiting inflammation and oxidant stress. Thus, GSK-3β inhibition may represent a potential therapeutic strategy for the prevention and treatment of CRAD.
Insights
Inhibiting glycogen synthase kinase 3β (GSK-3β) improved kidney function and reduced damage in a rat model of chronic renal allograft dysfunction (CRAD). This suggests GSK-3β inhibition is a promising strategy for treating CRAD by reducing inflammation and oxidative stress.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Chronic renal allograft dysfunction (CRAD) is a significant barrier to long-term kidney transplant survival.
- The underlying mechanisms of CRAD remain poorly understood, limiting effective treatment strategies.
- This study investigates the role of glycogen synthase kinase 3β (GSK-3β) in CRAD development.
Purpose of the Study:
- To evaluate the therapeutic potential of inhibiting GSK-3β in a rat model of CRAD.
- To elucidate the molecular mechanisms by which GSK-3β inhibition impacts CRAD progression.
Main Methods:
- An orthotopic renal transplantation model was established in rats to induce CRAD.
- The GSK-3β inhibitor, 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione, was administered for 12 weeks post-transplantation.
- Renal function, proteinuria, histological damage, and molecular markers of inflammation and oxidative stress were assessed.
Main Results:
- GSK-3β inhibition significantly improved renal function and reduced proteinuria and tissue damage in CRAD rats.
- Inhibition of GSK-3β suppressed inflammatory pathways, including nuclear factor-κB activation and macrophage infiltration.
- GSK-3β inhibition also mitigated oxidative stress by modulating key antioxidant enzymes and transcription factors.
Conclusions:
- Inhibition of GSK-3β effectively attenuates the development of CRAD.
- The protective effects are mediated through the suppression of inflammation and oxidative stress.
- Targeting GSK-3β presents a potential therapeutic avenue for preventing and treating chronic renal allograft dysfunction.
